Table 3 TQ total score with subscores (mean ± SD) at baseline and at week 16 (LOCF) including ANCOVA results from baseline to week 16 (LOCF) of ITT samples.
From: Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study
Vardenafil (N = 21) | Placebo (N = 21) | ||||||
|---|---|---|---|---|---|---|---|
TQ | Baseline | LOCF | Changes | Baseline | LOCF | Changes | p-valuea |
Total score | 34.9 ± 20.0 | 36.9 ± 21.3 | 2.0 ± 7.9 | 36.9 ± 21.0 | 35.2 ± 22.4 | -1.7 ± 12.4 | 0.29 |
Subscores Emotional distress | 9.1 ± 5.8 | 9.7 ± 6.5 | 0.6 ± 3.3 | 10.0 ± 7.1 | 9.3 ± 7.2 | -0.7 ± 4.0 | 0.29 |
Cognitive distress | 6.6 ± 4.6 | 6.6 ± 4.8 | 0 ± 1.8 | 7.0 ± 5.2 | 6.4 ± 5.5 | -0.6 ± 3.3 | 0.52 |
Intrusiveness of tinnitus | 9.8 ± 3.8 | 9.9 ± 3.6 | 0.1 ± 2.2 | 9.4 ± 3.9 | 8.9 ± 4.3 | -0.5 ± 2.9 | 0.34 |
Aud. perc. difficultiesb | 4.6 ± 4.5 | 5.7 ± 4.1 | 1.1 ± 2.4 | 5.3 ± 3.4 | 5.5 ± 4.1 | 0.2 ± 2.7 | 0.26 |
Sleep disturbances | 3.0 ± 2.6 | 3.0 ± 2.8 | 0 ± 1.2 | 3.2 ± 2.8 | 3.3 ± 3.0 | 0.1 ± 1.0 | 0.88 |
Somatic complaints | 1.9 ± 2.1 | 2.0 ± 2.3 | 0.1 ± 1.0 | 1.9 ± 1.7 | 1.9 ± 1.8 | 0 ± 1.5 | 0.81 |